US Specialty Care Continues to Demonstrate Superior Medication Adherence Rates
Newly diagnosed patients are often overwhelmed with information and unsure about how to take their prescribed medications. They may not understand the potential impact of their disease on their life and medication non-adherence continues to be one of the biggest barriers to effective treatment of disease states within the United States. An estimated 30% to 50% of American adults are not adherent to long-term medications, resulting in an estimated $100 billion in preventable costs annually. Patients with lower adherence rates are typically less likely to benefit from their prescribed regimen because they are not receiving optimal treatment for their condition, which may contribute to frequent visits to health care providers and higher health care costs. Specialty medications are very expensive, and it is critical that members maintain high adherence rates in order to receive the maximum benefit from their specialty medications.
US Specialty Care (USSC), WellDyneRx’s wholly-owned specialty pharmacy, strives to ensure excellence in improving the medication adherence rates of its members. First and foremost, USSC delivers exceptional service to drive the highest level of member satisfaction, which ultimately improves engagement with USSC. While most specialty pharmacies claim a high commitment to member satisfaction, US Specialty Care was named the winner of the Specialty Pharmacy Patient Choice Award™ (in the PBM/Payer Specialty Pharmacy category) during the 2017 Asembia Specialty Pharmacy Summit. The Patient Choice Award recognizes specialty pharmacies with the highest patient satisfaction ratings across the United States.
On average, 90% of USSC patients achieve targeted adherence levels. On average, this group has a 94% adherence rate, much higher than the industry benchmark of 80%. An article in the August 2017 issue of the peer-reviewed Journal of Managed Care and Specialty Pharmacy reported an average adherence rate of 96% for a specialty pharmacy that was part of a large, nationally recognized academic medical center. The article suggested that the key driver for their high level of adherence was due to pharmacists embedded within physician offices. In contrast, USSC achieves an annual adherence rate of 97% for our HIV patients, 93% for Multiple Sclerosis patients, 94% for Psoriasis patients, 93% for Rheumatoid Arthritis patients, and 98% for Ulcerative Colitis and Hepatitis C patients. We achieve equal and/or greater adherence outcomes through our high level of member and provider engagement, despite not having pharmacists directly located in physician offices. To further contrast our medication adherence against another industry leader, Express Scripts reported in their 2016 Annual Drug Trend Report that 41.5% of Rheumatoid Arthritis members are not adherent to treatment and 23.9% of multiple sclerosis members are not adherent to therapy. For the most recent 12 month period, USSC only had 7% of MS members and 12% of RA patients who were nonadherent to treatment.
USSC continues to achieve superior medication adherence rates when compared to both industry standards and benchmarks. Improved medication adherence has been demonstrated in multiple studies to help lower overall healthcare costs and improve overall quality of life. USSC, with its strong focus and commitment to excellence, builds and fosters relationships with both patients and providers to ensure barriers to medication adherence are mitigated and controlled.
2018 Quarter One WellInformed Table Contents